Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 2
2007 2
2008 2
2009 2
2010 2
2011 1
2012 3
2013 3
2014 1
2015 1
2016 1
2017 1
2018 1
2019 4
2020 2
2021 3
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing.
Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Kürten CHL, et al. Among authors: vujanovic l. Nat Commun. 2021 Dec 17;12(1):7338. doi: 10.1038/s41467-021-27619-4. Nat Commun. 2021. PMID: 34921143 Free PMC article.
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Ferris RL, et al. Among authors: vujanovic l. J Immunother Cancer. 2021 Jun;9(6):e002568. doi: 10.1136/jitc-2021-002568. J Immunother Cancer. 2021. PMID: 34083421 Free PMC article. Clinical Trial.
Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms.
Chandra J, Hansen M, Labarriere N, Marigo I, Souza-Fonseca-Guimaraes F, Vujanovic L, Koguchi Y, Jacquelot N. Chandra J, et al. Among authors: vujanovic l. Front Immunol. 2022 Jun 2;13:939789. doi: 10.3389/fimmu.2022.939789. eCollection 2022. Front Immunol. 2022. PMID: 35720421 Free PMC article. No abstract available.
Tumor cell p38 inhibition to overcome immunotherapy resistance.
Luke JJ, Dadey RE, Augustin RC, Newman S, Singh KB, Doerfler R, Behr S, Lee P, Isett B, Deitrick C, Li A, Joy M, Reeder C, Smith K, Urban J, Sellitto L, Jelinek M, Christner SM, Beumer JH, Villaruz LC, Kulkarni A, Davar D, Poklepovic AS, Najjar Y, Zandberg DP, Soloff AC, Bruno TC, Vujanović L, Skinner HD, Ferris RL, Bao R. Luke JJ, et al. Among authors: vujanovic l. Res Sq [Preprint]. 2023 Aug doi: 10.21203/ Res Sq. 2023. PMID: 37645831 Free PMC article. Preprint.
Melanoma vaccines: clinical status and immune endpoints.
Maurer DM, Butterfield LH, Vujanovic L. Maurer DM, et al. Among authors: vujanovic l. Melanoma Res. 2019 Apr;29(2):109-118. doi: 10.1097/CMR.0000000000000535. Melanoma Res. 2019. PMID: 30802228 Free PMC article.
An individualized causal framework for learning intercellular communication networks that define microenvironments of individual tumors.
Chen X, Chen L, Kürten CHL, Jabbari F, Vujanovic L, Ding Y, Lu B, Lu K, Kulkarni A, Tabib T, Lafyatis R, Cooper GF, Ferris R, Lu X. Chen X, et al. Among authors: vujanovic l. PLoS Comput Biol. 2022 Dec 22;18(12):e1010761. doi: 10.1371/journal.pcbi.1010761. eCollection 2022 Dec. PLoS Comput Biol. 2022. PMID: 36548438 Free PMC article.
39 results